Candid Therapeutics
San Diego, US · Founded 2024 · Delaware corporation · 38 employees on LinkedIn · 7 known investors
CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells. The company focuses on creating therapies that are more effective and easier to administer than existing antibody and cell therapy approaches.
Founders & leadership
Candid Therapeutics was founded in 2024 by Ken Song and Kenneth Song, M.D..
KS
Ken SongChairman, President and CEO
KS
Kenneth Song, M.D.Co-founder
AK
Arvind KushExecutive
TL
Timothy Lu, M.D.Executive
BH
Bernie Huyghe, Ph.D.Executive
Board
JT
Jeffrey Tong, Ph.D.Board director
AR
Aaron Royston, M.D.Board director
MR
Michael Rome, M.D.Board director
Investors · 7
Reported raises · per SEC filings
Form D private placements$206.2M disclosed across 1 round · 2024
▶$206.2MraisedSep 2024 · 33 investors · Other Health CareRule 506(b)
▶$206.2MraisedSep 2024 · 33 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Jeffrey Tong, Ph.D.Director
- Arvind KushExecutive Officer
- Timothy Lu, M.D.Executive Officer
- Kenneth Song, M.D.Executive Officer, Director
- Aaron Royston, M.D.Director
- Bernie Huyghe, Ph.D.Executive Officer
- Michael Rome, M.D.Director
- Offering amount
- $206.2M
- Amount sold
- $206.2M
- First sale
- Aug 2024
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlap
Obsidiantx10 shared keywordsObsidian Therapeutics develops engineered TIL (tumor-infiltrating lymphocyte) cell therapies for patients with solid tumors, with a lead clinical program (amsoki-cel / OBX-115) treating metastatic melanoma and non-small cell lung cancer. It also licenses its cytoDRiVE platform technology through partnerships to discover novel therapies.
Bioworld9 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Dialectic Therapeutics7 shared keywordsDialectic Therapeutics is a clinical-stage biotechnology company developing anti-cancer drugs using its Antiapoptotic Protein Targeted Degradation (APTaD) platform, which induces cancer cells to degrade proteins such as BCL-XL. Its lead candidate, DT2216, is in Phase 1/2 trials for fibrolamellar carcinoma and platinum-resistant ovarian cancer.
Companies competing with Candid Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Cancer, immune drugmakers dominate VC funding so far in 2026 | BioPharma Divebiopharmadive.com · Jul 2026Frequently asked questions
- What does Candid Therapeutics do?
- CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells. The company focuses on creating therapies that are more effective and easier to administer than existing antibody and cell therapy approaches.
- Who founded Candid Therapeutics?
- Candid Therapeutics was founded by Ken Song, Kenneth Song, M.D. in 2024.
- Who are Candid Therapeutics's investors?
- Candid Therapeutics's investors include Foresite Capital, OrbiMed, Samsara BioCapital, TCG Crossover, Third Rock Ventures, venBio Partners, Vida Ventures.
- How much funding has Candid Therapeutics raised?
- Candid Therapeutics has disclosed $206.2M raised across 1 round.
- Where is Candid Therapeutics headquartered?
- Candid Therapeutics is headquartered in San Diego, US.